Alain Beck | Senior Director
Centre d'Immunologie Pierre Fabre

Alain Beck is Senior Director, Biologics CMC and developability, Pierre Fabre Laboratories (FR). He is associated editor of mAbs (USA) and mAbDesign advisor board chairman (www.mabdesign.fr). He has contributed to the R&D of immuno-oncology mAbs, clinical stages mAbs and ADCs in oncology (dalotuzumab/IGF-1R licensed to Merck; telisotuzumab and telisotuzumab vedotin/cMet, licensed to AbbVie; h515H7/CXCR4 and W0101 ADC/IGF-1R), peptides and vaccines (RSV, ELA/P40). He has published +260 papers and reports on mAbs, biosimilars, biobetters, ADCs, bsAbs, Fc-fusions, protein scaffolds, structure/function relationships, stability, comparability and developability (h-index: 70; +17600 citations). He was involved in more than 300 scientific meetings (AIS, ASMS, BAS, CASSS, EAC, GlycoBiotec, HPLC, IBC, IMSC, ISC, PEGS, SEP, WADC, WBC) as chairperson, invited plenary/ keynote speaker, panelist, moderator, advisor, and organizer as well as to meetings and workshops with regulatory or standardization agencies (ANSM, EMA, EDQM/PhEur, FDA, PEI, USP, WHO). He was ranked 6/50 global antibody industry influencers (www.antibodysociety.org).